Live feed00:12:26·286dPRReleasevia QuantisnowAmgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic DermatitisByQuantisnow·Wall Street's wire, on your screen.AMGN· Amgen Inc.Health Care